Jade Biosciences, Inc. JBIO
14.42
(0.31)
(2.10%)
as of 25 Sep
- Market cap
- $936.8M
- P/E
- 0.0×
Follow JBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
9.01 | 21.09 | 14.29 | 14.93 |
Net Debt/EBITDA |
7.22 | 9.45 | 7.09 | 7.78 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 7.22 | 0.60 | 0.78 | |
Capex/Depreciation |
0.35 | 0.01 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.56) | (1.07) | (0.42) | (0.72) | |
Cash per Share |
5.02 | 10.72 | 5.39 | 7.55 | |
Shareholders Equity per Share |
4.53 | 10.60 | 5.13 | 7.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.53 | 10.60 | 5.13 | 7.21 | |
Free Cash Flow |
(22.18) | (33.65) | (24.08) | (43.66) | |
Working Capital |
179.00 | 332.28 | 296.23 | 439.68 | |
Capital Expenditures |
(0.06) | 0.00 | — | — | |
Net Current Asset Value |
178.26 | 331.55 | 295.55 | 439.05 | |
| Other line items | |||||
Quick Ratio |
8.90 | 20.33 | 13.96 | 14.61 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.56) | (1.07) | (0.42) | (0.72) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.13 | 1.72 | 2.02 | 7.08 | |
Average Assets |
146.70 | 211.29 | 198.48 | 348.04 | |
Average Common Equity |
129.92 | 142.86 | 185.75 | 320.73 | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates